In yesterday’s Wall Street session, Qiagen N.V. (NYSE:QGEN) shares traded at $46.85, up 0.06% from the previous session.
As of this writing, 20 analysts cover Qiagen N.V. (NYSE:QGEN). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $62.07 and a low of $42.00, we find $54.00. Given the previous closing price of $46.82, this indicates a potential upside of 15.34 percent. QGEN stock price is now 2.46% away from the 50-day moving average and 0.29% away from the 200-day moving average. The market capitalization of the company currently stands at $10.59B.
There are 11 analysts who have given it a hold rating, whereas 8 have given it a buy rating. Brokers who have rated the stock have averaged $53.48 as their price target over the next twelve months.
Insiders disposed of 349,878 shares of company stock worth roughly $16.39 million over the past 1 year. A total of 3.60% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in QGEN stock. A new stake in Qiagen N.V. shares was purchased by DAVIDSON KEMPNER PARTNERS during the first quarter worth $79,889,000. ING GROEP NV invested $22,135,000 in shares of QGEN during the first quarter. In the first quarter, MACKENZIE FINANCIAL CORP acquired a new stake in Qiagen N.V. valued at approximately $17,026,000. SEGALL BRYANT & HAMILL, LLC acquired a new stake in QGEN for approximately $6,692,000. NINETY ONE UK LTD purchased a new stake in QGEN valued at around $4,727,000 in the second quarter.
Wednesday morning saw Qiagen N.V. (NYSE: QGEN) opened at $46.63. During the past 12 months, Qiagen N.V. has had a low of $40.38 and a high of $51.18. As of last week, the company has a debt-to-equity ratio of 0.53, a current ratio of 2.50, and a quick ratio of 2.10. According to the stock market information, the enterprise value for the company is $11.27B, which is based on a 30.56 price-to-earnings ratio, a 12.42 price-to-earnings-growth ratio, and a beta of 0.36. The fifty day moving average price for QGEN is $45.76 and a two-hundred day moving average price translates $46.73 for the stock.
According to the Diagnostics & Research Company, earnings per share came in at $0.51, beating analysts’ expectations of $0.47 by 0.04. This compares to $0.67 EPS in the same period last year. The net profit margin was 17.70% and return on equity was 10.40% for QGEN. The company reported revenue of $485.4 million for the quarter, compared to $628.39 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -22.76 percent. For the current quarter, analysts expect QGEN to generate $492.51M in revenue.
